Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Unknown 3Withdrawn 2Recruiting 1Not yet recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3Gastrointestinal 2Tumor-Agnostic 1Other hematologic neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Adenocarcinoma of Lung 1

Interventions

Carboplatin 132Cisplatin 129Pemetrexed 114Docetaxel 81Drug Therapy 62Gefitinib 57anlotinib 55Gemcitabine 55Erlotinib Hydrochloride 55Radiotherapy 48Bevacizumab 48pembrolizumab 47Paclitaxel 47Etoposide 44apatinib 42icotinib 41camrelizumab 39osimertinib 36Nivolumab 33Vinorelbine 31Radiosurgery 30sintilimab 29durvalumab 25aumolertinib 25endostar protein 24atezolizumab 22Endostatins 22toripalimab 19Blood Specimen Collection 19tislelizumab 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Unknown × Thymalfasin × Thoracic × Clear all
NCT02787447 2016-11-25

Radiotherapy Combined With Thymosin for Metastatic NSCLC Patients Who Showed Stable Disease After First Line TKI Therapy

First People's Hospital of Hangzhou

Phase 2 Unknown
46 enrolled
Thoracic

Adenocarcinoma of Lung

NCT02906150 2016-09-19

Thymosin Alpha 1 Plus Maintenance Therapy With the Standard of Care (SoC) in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC), EGFR Wild Type

SciClone Pharmaceuticals

Phase 2 Unknown
140 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02906163 2016-09-19

First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy

SciClone Pharmaceuticals

Phase 1/2 Unknown
188 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡